Efficacy and Safety of TAR-200 vs. Intravesical Chemotherapy in High-Risk Non-Muscle-Invasive Bladder Cancer Post-BCG Recurrence

The primary objective of this Phase 3, randomized, open-label, multi-center study is to compare **disease-free survival (DFS)** in participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have recurred after receiving Bacillus Calmette-Guérin (BCG) therapy and are ineligible for or have elected not to undergo radical cystectomy. This objective is clinically relevant as it aims to evaluate the efficacy of TAR-200 compared to the investigator’s choice of intravesical chemotherapy, potentially offering an alternative treatment option for patients with limited surgical options.

The clinical trial involves a total of **146 participants** diagnosed with **High-Risk Non-muscle-invasive Bladder Cancer**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected based on specific inclusion criteria, such as a histologically confirmed diagnosis of recurrent, papillary-only HR-NMIBC, and having received adequate induction doses of BCG therapy. The trial population includes individuals who are ineligible for or have chosen not to undergo radical cystectomy. The study does not specify particular lifestyle considerations such as diet or physical activity. The trial also includes a vulnerable population, indicating that additional ethical considerations are in place to protect these participants.

The clinical trial is a **Phase 3**, randomized, open-label, multi-center study designed to evaluate the efficacy and safety of TAR-200 compared to the investigator's choice of intravesical chemotherapy in participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have previously received Bacillus Calmette-Guérin (BCG) and have recurred. The trial aims to compare disease-free survival (DFS) as the primary endpoint, measuring the time from randomization to the first recurrence of HR-NMIBC, progression, or death due to any cause. The study is expected to conclude by March 2031, with recruitment starting in May 2024.

Participants will be randomly assigned to receive either the investigational product or the comparator. The investigational product, TAR-200, is administered intravesically, while the comparator involves the use of either **mitomycin** or **gemcitabine hydrochloride**, also administered intravesically. The trial includes a screening visit to confirm eligibility, followed by regular follow-up visits to monitor the participants' health and response to treatment. The end-of-study visit will assess the final outcomes and any adverse events experienced during the trial.

The expected duration of participant involvement is approximately 96 weeks, with conditions for early termination including significant adverse events, disease progression, or withdrawal of consent. Participants must have a histologically confirmed diagnosis of recurrent, papillary-only HR-NMIBC, with all visible tumors resected prior to randomization. They must have received at least five of six induction doses of BCG and be ineligible for or have elected not to undergo radical cystectomy. The trial excludes participants with neuroendocrine or small cell variants of the disease.

The clinical trial involves the administration of **Mitomycin**, an experimental medication, which is utilized in the treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Mitomycin is a chemical substance with the active ingredient **Mitomycin C**. It is administered in a pharmaceutical form designated as PHF675. The route of administration is **intravesical use**, which involves delivering the medication directly into the bladder. The maximum daily dose is 40 mg, with a total treatment period extending up to 96 weeks. Participant compliance with the dosing schedule is monitored throughout the trial.

In addition to Mitomycin, the study includes a comparator treatment, **Gemcitabine Hydrochloride**, which is also a chemical substance. This comparator is provided in two different pharmaceutical forms. The first form is a tablet, identified by the sponsor product code JNJ-17000139, and is manufactured by Janssen-Cilag International N.V. The second form is designated as PHF00230MIG. Both forms of Gemcitabine Hydrochloride are administered via intravesical use. The maximum daily dose for the PHF00230MIG form is 2000 mg, with a treatment period of up to 96 weeks. The tablet form does not have a specified maximum daily dose in the trial data. Compliance with the administration schedule is similarly monitored for participants receiving this treatment.

The efficacy of the clinical trial will be assessed primarily through the measurement of **disease-free survival (DFS)**. DFS is defined as the time from randomization to the first occurrence of recurrence of high-risk non-muscle-invasive bladder cancer (HR-NMIBC), progression, or death due to any cause. The recurrence or progression events for DFS will be determined by central disease assessments, which may include urine cytology, bladder biopsy, or imaging, as applicable. These assessments will be conducted to ensure accurate and consistent evaluation of the primary endpoint.